Literature DB >> 32700129

Potential therapeutic effects of electrogram-guided cardioneuroablation in long QT syndrome: case series.

Tolga Aksu1, Tumer Erdem Guler2, Serdar Bozyel2, Kivanc Yalin3, Rakesh Gopinathannair4.   

Abstract

BACKGROUND: A significant shortening of the corrected QT interval (QTc) in addition to parasympathetic denervation after cardioneuroablation (CNA) was recently demonstrated in patients with vagally mediated bradyarrhythmias and normal QTc range. This study assessed the effects of CNA on ventricular repolarization and heart rate by using QTc measurements in 2 patients with long QT syndrome (LQTS).
METHODS: The case series included 2 consecutive patients with significant sinus bradycardia and refractory paroxysmal atrial fibrillation (AF). All atrial ganglionated plexus (GP) sites in addition to pulmonary vein isolation were successively targeted by using electrogram-guided strategy. QTc was calculated on 12-lead ECG before the procedure (time point 1), at post-ablation 24 h (time point 2), and at the last follow-up visit (time point 3), respectively.
RESULTS: In the first case, QTc (Bazett) shortened from 612 to 551 msec between time points 1 and 2 and was 419 msec in time point 3. Similarly, QTc (Bazett) shortened from 480 to 401 msec between time points 1 and 3 in the second case. In both cases, minimum and mean heart rates were significantly increased after ablation. The parameters of which are used to estimate both sympathetic and parasympathetic changes in heart rate variability were significantly decreased after ablation. There were no arrhythmia-related symptoms during follow-up.
CONCLUSIONS: The present case series reports a new ablation strategy systematically targeting autonomic GPs in LQTS patients. CNA shortens QTc (through sympathetic modulation) and increases heart rate. Although promising, these preliminary results need to be confirmed in the larger prospective study.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Ablation; Atrial fibrillation; Bradycardia; Ganglionated plexus; Syncope

Year:  2020        PMID: 32700129     DOI: 10.1007/s10840-020-00831-w

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  2 in total

Review 1.  2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).

Authors:  Silvia G Priori; Carina Blomström-Lundqvist; Andrea Mazzanti; Nico Blom; Martin Borggrefe; John Camm; Perry Mark Elliott; Donna Fitzsimons; Robert Hatala; Gerhard Hindricks; Paulus Kirchhof; Keld Kjeldsen; Karl-Heinz Kuck; Antonio Hernandez-Madrid; Nikolaos Nikolaou; Tone M Norekvål; Christian Spaulding; Dirk J Van Veldhuisen
Journal:  Europace       Date:  2015-08-29       Impact factor: 5.214

2.  Catheter Ablation as a Treatment for Vasovagal Syncope: Long-Term Outcome of Endocardial Autonomic Modification of the Left Atrium.

Authors:  Wei Sun; Lihui Zheng; Yu Qiao; Rui Shi; Bingbo Hou; Lingmin Wu; Jinrui Guo; Shu Zhang; Yan Yao
Journal:  J Am Heart Assoc       Date:  2016-07-08       Impact factor: 5.501

  2 in total
  3 in total

1.  Left Atrial Size May Predict Blood Pressure Improvement After Ganglionated Plexi Ablation in Addition to Pulmonary Vein Isolation.

Authors:  Daniel Sohinki; Isma Javed; Benjamin Scherlag; Wesley Thomas; Sunny Po; Tarun Dasari
Journal:  J Atr Fibrillation       Date:  2020-08-31

2.  Mysteries of Ganglionated Plexi Ablation: More to Learn.

Authors:  Tolga Aksu; Rakesh Gopinathannair
Journal:  J Atr Fibrillation       Date:  2020-12-31

3.  Recurrent vasovagal syncope following successful cardioneuroablation.

Authors:  Clinton J Thurber; Davis R Sneider; William H Sauer; Sunil Kapur
Journal:  HeartRhythm Case Rep       Date:  2022-04-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.